Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial–mesenchymal transition in non‐small cell lung cancer
暂无分享,去创建一个
[1] M. Stack,et al. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III , 2006, Molecular carcinogenesis.
[2] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[3] G. Cavet,et al. Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients , 2005, Clinical Cancer Research.
[4] E. Brown,et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. , 2005, Cancer research.
[5] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[6] William Pao,et al. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Shih-Feng Tsai,et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.
[8] A. Bezjak,et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial , 2004 .
[9] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[10] S. Wiseman,et al. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry , 2004, Modern Pathology.
[11] J. Baselga. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] V. Tkach,et al. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility , 2004, International journal of cancer.
[13] Jean Paul Thiery,et al. Epithelial-mesenchymal transitions in development and pathologies. , 2003, Current opinion in cell biology.
[14] L. Trusolino,et al. Interactions between growth factor receptors and adhesion molecules: breaking the rules. , 2003, Current opinion in cell biology.
[15] H. Beug,et al. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis , 2003, Nature Reviews Molecular Cell Biology.
[16] Alfonso Bellacosa,et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. , 2003, Cancer research.
[17] M. Frame,et al. Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.
[18] J. Thiery,et al. Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. , 2002, Journal of cell science.
[19] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[20] E. Gabrielson,et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Downward,et al. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis , 2002, The Journal of Cell Biology.
[22] Cody Schrank,et al. American Cancer Society , 2005 .
[23] B. Freidlin,et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Kris,et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] E. Dmitrovsky,et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.
[26] A. Jemal,et al. Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.
[27] A. Bezjak,et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] L. Damstrup,et al. Epidermal growth factor receptor mutation type iii transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype , 2002, International journal of cancer.
[29] J. Downward,et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. , 2002, The Journal of cell biology.